Pipelines

Allogene builds allogeneic CAR-T site, looking ahead to ‘commercial product’

27-Feb-2019 By Ben Hargreaves

Allogene enters a lease agreement to develop a 118,000-square-foot site for the manufacture of allogeneic CAR-T therapies.

‘Production efficiency’ crucial in ‘battle of biosimilars’

25-Feb-2019 By Ben Hargreaves

Celltrion Healthcare’s head of medical and marketing outlines how the US biosimilar market is evolving and how manufacturing efficiency could become a key distinguisher from competitors.

Roche buys into gene therapies with $4.8bn Spark acquisition

25-Feb-2019 By Ben Hargreaves

Roche gains access to Spark’s potential gene therapy treatments for haemophilia to complement its existing portfolio in the space.

MedImmune will cease to exist after 30 years

18-Feb-2019 By Ben Hargreaves

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

WuXi Biologics enters first commercial manufacturing agreement

13-Feb-2019 By Ben Hargreaves

WuXi Biologics agrees five-year deal with Amicus for the commercial production of a biologic for the treatment of Pompe disease.

Samsung Bioepis expands in China with second partner in two months

12-Feb-2019 By Ben Hargreaves

Samsung Bioepis announces licensing agreement with C-Bridge to bring ‘third-wave’ biosimilars to the Chinese market.

Biosimilar entry into US insulin market will see ‘millions more patients treated’

11-Feb-2019 By Ben Hargreaves

The US market for insulin biosimilars is set to open up in 2020, and the head of biopharmaceuticals at Sandoz explained why he is confident of an ‘acceleration’ of the US biosimilar market in the coming years.

CAR-T for solid tumors drives industry to innovate

08-Feb-2019 By Maggie Lynch

ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.

Teva highlights quarterly dosing of migraine med as EU gives positive opinion

07-Feb-2019 By Ben Hargreaves

After a CHMP positive opinion, Teva’s Ajovy looks set to receive final approval to enter the EU market in the coming months.

GSK indicates oncology intent with €3.7bn Merck deal

05-Feb-2019 By Ben Hargreaves

GSK moves to rebuild its oncology pipeline by partnering with Merck KGaA on an immuno-oncology drug candidate.

Alzheimer’s disease: Despite failures, hope for new treatment by 2025

04-Feb-2019 By Ben Hargreaves

Despite Roche’s recent trial failure for crenezumab, the ProMIS team remain confident a disease-modifying treatment will be found in the next decade.

Neurocrine agrees to pay up to $1.7bn in gene therapy collaboration

31-Jan-2019 By Maggie Lynch

Neurocrine and Voyager enter an agreement to fund and develop gene therapy candidates for the treatment of severe neurological diseases.

Regulators rule no new patients for Lilly’s oncology drug

29-Jan-2019 By Ben Hargreaves

After Lartruvo failed to show efficacy in trials, the EMA and FDA advised that no new patients should take the drug in combination with chemotherapy.

Five reasons biologics contract manufacturing will hit $87.6bn by 2027

25-Jan-2019 By Ben Hargreaves

The contract market for bringing biologics through the pipeline to commercialisation is growing at a rapid clip, with a recent report suggesting a high CAGR in the sector.

Celgene licenses immuno-oncology pipeline in $80m deal

23-Jan-2019 By Maggie Lynch

Celgene and Kyn Therapeutics enter a licensing agreement to develop Kyn’s immuno-oncology pipeline for investigative therapies after Celgene was acquired by BMS.